+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antihypertensive Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 5005275
  • Report
  • January 2020
  • Region: Global
  • 213 pages
  • Transparency Market Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • MORE
Antihypertensive Drugs Market – Scope of the Report

This report on the global antihypertensive drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the antihypertensive drugs market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the antihypertensive drugs market for the forecast period.

The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the antihypertensive drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the antihypertensive drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the antihypertensive drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the antihypertensive drugs market. The next section of the antihypertensive drugs report highlights the USPs, which include regulatory scenario, reimbursement scenario, key mergers & acquisitions, technological advancements, and key industry developments in the antihypertensive drugs market.

The report delves into the competitive landscape of the antihypertensive drugs market. Key players operating in the antihypertensive drugs market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the antihypertensive drugs market profiled in this report.

Key Questions Answered
  • What are the major drivers, restraints, and opportunities in the market?
  • What will be the revenue share projections of key segments in the antihypertensive drugs market during the forecast period?
  • Which segment is likely to lead the antihypertensive drugs market in terms of revenue by 2027?
  • How mergers & acquisitions among players are widening the scope for antihypertensive drugs market?
  • What are the market positions of different companies operating in the global antihypertensive drugs market?
Research Objectives and Research Approach

The comprehensive report on the antihypertensive drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides a detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of research in the antihypertensive drugs market. It is followed by market introduction, market dynamics, and an overview of the antihypertensive drugs market, which includes analysis of market drivers, restraints, and trends affecting the growth of the antihypertensive drugs market. Furthermore, to understand the Y-o-Y trends of the antihypertensive drugs market, a Y-o-Y analysis with elaborated insights on the same has been provided. The next section of the antihypertensive drugs report highlights the USPs, which include regulatory scenario, reimbursement scenario, key mergers & acquisitions, technological advancements, and key industry developments in the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the antihypertensive drugs market in terms of drug, condition, medication type, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investments in the antihypertensive drugs market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • MORE

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antihypertensive Drugs Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
5.1. Key Industry Developments
5.2. Regulatory Scenario
5.3. Reimbursement Scenario
5.4. Key Mergers & Acquisitions
5.5. Technological Advancements

6. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug
6.1. Introduction & Definition
6.2. Global Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2027
6.2.1. Diuretics
6.2.1.1. Thiazide Diuretics
6.2.1.2. Loop Diuretics
6.2.1.3. Potassium-sparing Diuretics
6.2.2. Angiotensin Converting Enzyme Inhibitors
6.2.3. Angiotensin Receptor Blockers
6.2.4. Beta-blockers
6.2.4.1. Beta-1 Selective
6.2.4.2. Intrinsic Sympathomimetic
6.2.5. Vasodilators
6.2.6. Calcium Channel Blockers
6.2.7. Renin Inhibitors
6.2.8. Alpha-blockers
6.2.9. Others
6.3. Global Antihypertensive Drugs Market Attractiveness, by Drug

7. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition
7.1. Introduction & Definition
7.2. Global Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2027
7.2.1. Primary Hypertension
7.2.2. Secondary Hypertension
7.3. Global Antihypertensive Drugs Market Attractiveness, by Condition

8. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type
8.1. Introduction
8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2027
8.2.1. Monotherapy
8.2.2. Combination Therapy
8.2.3. Fixed Dose Combinations
8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type

9. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel
9.1. Introduction
9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2027
9.2.1. Retail Pharmacies
9.2.2. Hospital Pharmacies
9.2.3. Online Pharmacies
9.2.4. Others
9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel

10. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Region
10.1. Introduction
10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017–2027
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa  
10.3. Global Antihypertensive Drugs Market Attractiveness, by Region

11. North America Antihypertensive Drugs Market Analysis and Forecast
11.1. Introduction
11.2. North America Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2027
11.2.1. Diuretics
11.2.1.1. Thiazide Diuretics
11.2.1.2. Loop Diuretics
11.2.1.3. Potassium-sparing Diuretics
11.2.2. Angiotensin Converting Enzyme Inhibitors
11.2.3. Angiotensin Receptor Blockers
11.2.4. Beta-blockers
11.2.4.1. Beta-1 Selective
11.2.4.2. Intrinsic Sympathomimetic
11.2.5. Vasodilators
11.2.6. Calcium Channel Blockers
11.2.7. Renin Inhibitors
11.2.8. Alpha-blockers
11.2.9. Others
11.3. North America Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2027
11.3.1. Primary Hypertension
11.3.2. Secondary Hypertension
11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2027
11.4.1. Monotherapy
11.4.2. Combination Therapy
11.4.3. Fixed Dose Combinations
11.4.4. Others
11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2027
11.5.1. Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Online Pharmacies
11.5.4. Others
11.6. North America Antihypertensive Drugs Market Value Forecast, by Country, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
11.7.1. By Drug
11.7.2. By Condition
11.7.3. By Medication Type
11.7.4. By Distribution Channel
11.7.5. By Country

12. Europe Antihypertensive Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Europe Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2027
12.2.1. Diuretics
12.2.1.1. Thiazide Diuretics
12.2.1.2. Loop Diuretics
12.2.1.3. Potassium-sparing Diuretics
12.2.2. Angiotensin Converting Enzyme Inhibitors
12.2.3. Angiotensin Receptor Blockers
12.2.4. Beta-blockers
12.2.4.1. Beta-1 Selective
12.2.4.2. Intrinsic Sympathomimetic
12.2.5. Vasodilators
12.2.6. Calcium Channel Blockers
12.2.7. Renin Inhibitors
12.2.8. Alpha-blockers
12.2.9. Others
12.3. Europe Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2027
12.3.1. Primary Hypertension
12.3.2. Secondary Hypertension
12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2027
12.4.1. Monotherapy
12.4.2. Combination Therapy
12.4.3. Fixed Dose Combinations
12.4.4. Others
12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2027
12.5.1. Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Online Pharmacies
12.5.4. Others
12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
12.7.1. By Drug
12.7.2. By Condition
12.7.3. By Medication Type
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region

13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2027
13.2.1. Diuretics
13.2.1.1. Thiazide Diuretics
13.2.1.2. Loop Diuretics
13.2.1.3. Potassium-sparing Diuretics
13.2.2. Angiotensin Converting Enzyme Inhibitors
13.2.3. Angiotensin Receptor Blockers
13.2.4. Beta-blockers
13.2.4.1. Beta-1 Selective
13.2.4.2. Intrinsic Sympathomimetic
13.2.5. Vasodilators
13.2.6. Calcium Channel Blockers
13.2.7. Renin Inhibitors
13.2.8. Alpha-blockers
13.2.9. Others
13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2027
13.3.1. Primary Hypertension
13.3.2. Secondary Hypertension
13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2027
13.4.1. Monotherapy
13.4.2. Combination Therapy
13.4.3. Fixed Dose Combinations
13.4.4. Others
13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2027
13.5.1. Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Online Pharmacies
13.5.4. Others
13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2027
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
13.7.1. By Drug
13.7.2. By Condition
13.7.3. By Medication Type
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region

14. Latin America Antihypertensive Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2027
14.2.1. Diuretics
14.2.1.1. Thiazide Diuretics
14.2.1.2. Loop Diuretics
14.2.1.3. Potassium-sparing Diuretics
14.2.2. Angiotensin Converting Enzyme Inhibitors
14.2.3. Angiotensin Receptor Blockers
14.2.4. Beta-blockers
14.2.4.1. Beta-1 Selective
14.2.4.2. Intrinsic Sympathomimetic
14.2.5. Vasodilators
14.2.6. Calcium Channel Blockers
14.2.7. Renin Inhibitors
14.2.8. Alpha-blockers
14.2.9. Others
14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2027
14.3.1. Primary Hypertension
14.3.2. Secondary Hypertension
14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2027
14.4.1. Monotherapy
14.4.2. Combination Therapy
14.4.3. Fixed Dose Combinations
14.4.4. Others
14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2027
14.5.1. Retail Pharmacies
14.5.2. Hospital Pharmacies
14.5.3. Online Pharmacies
14.5.4. Others
14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Antihypertensive Drugs Market Attractiveness Analysis
14.7.1. By Drug
14.7.2. By Condition
14.7.3. By Medication Type
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region

15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Drug, 2017–2027
15.2.1. Diuretics
15.2.1.1. Thiazide Diuretics
15.2.1.2. Loop Diuretics
15.2.1.3. Potassium-sparing Diuretics
15.2.2. Angiotensin Converting Enzyme Inhibitors
15.2.3. Angiotensin Receptor Blockers
15.2.4. Beta-blockers
15.2.4.1. Beta-1 Selective
15.2.4.2. Intrinsic Sympathomimetic
15.2.5. Vasodilators
15.2.6. Calcium Channel Blockers
15.2.7. Renin Inhibitors
15.2.8. Alpha-blockers
15.2.9. Others
15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Condition, 2017–2027
15.3.1. Primary Hypertension
15.3.2. Secondary Hypertension
15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2027
15.4.1. Monotherapy
15.4.2. Combination Therapy
15.4.3. Fixed Dose Combinations
15.4.4. Others
15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017–2027
15.5.1. Retail Pharmacies
15.5.2. Hospital Pharmacies
15.5.3. Online Pharmacies
15.5.4. Others
15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Israel
15.6.4. Rest of Middle East & Africa
15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
15.7.1. By Drug
15.7.2. By Condition
15.7.3. By Medication Type
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region

16. Competition Landscape
16.1. Global Antihypertensive Drugs Market Share Analysis, by Company (2018)
16.2.  Company Profiles
16.2.1. Pfizer Inc.
16.2.1.1. Company Description
16.2.1.2. Business Overview
16.2.1.3. Financial Overview
16.2.1.4. Strategic Overview
16.2.1.5. SWOT Analysis
16.2.2. Sanofi S.A
16.2.2.1. Company Description
16.2.2.2. Business Overview
16.2.2.3. Financial Overview
16.2.2.4. Strategic Overview
16.2.2.5. SWOT Analysis
16.2.3. Novartis AG
16.2.3.1. Company Description
16.2.3.2. Business Overview
16.2.3.3. Financial Overview
16.2.3.4. Strategic Overview
16.2.3.5. SWOT Analysis
16.2.4. Boehringer Ingelheim GmbH
16.2.4.1. Company Description
16.2.4.2. Business Overview
16.2.4.3. Financial Overview
16.2.4.4. Strategic Overview
16.2.4.5. SWOT Analysis
16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
16.2.5.1. Company Description
16.2.5.2. Business Overview
16.2.5.3. Financial Overview
16.2.5.4. Strategic Overview
16.2.5.5. SWOT Analysis
16.2.6. F. Hoffmann-La Roche Ltd.
16.2.6.1. Company Description
16.2.6.2. Business Overview
16.2.6.3. Financial Overview
16.2.6.4. Strategic Overview
16.2.6.5. SWOT Analysis
16.2.7. Bayer AG
16.2.7.1. Company Description
16.2.7.2. Business Overview
16.2.7.3. Financial Overview
16.2.7.4. Strategic Overview
16.2.7.5. SWOT Analysis
16.2.8. Daiichi Sankyo Company, Limited
16.2.8.1. Company Description
16.2.8.2. Business Overview
16.2.8.3. Financial Overview
16.2.8.4. Strategic Overview
16.2.8.5. SWOT Analysis
16.2.9. Takeda Pharmaceutical Company Limited
16.2.9.1. Company Description
16.2.9.2. Business Overview
16.2.9.3. Financial Overview
16.2.9.4. Strategic Overview
16.2.9.5. SWOT Analysis

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer Inc.
  • Sanofi S.A
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Actelion Ltd. (Johnson & Johnson Services, Inc.)
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Daiichi Sankyo Company, Limited
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
Adroll
adroll